Grail distribution partnership with Quest a positive, says Guggenheim

Guggenheim analyst Subbu Nambi noted that Grail (GRAL) announced a partnership yesterday with Quest Diagnostics (DGX) to offer Galleri, Grail’s multi-cancer early detection, or MCED, test. The firm, which views this distribution partnership as a positive for Grail as it simplifies the ordering process and leverages Quest’s network and infrastructure to make Galleri more accessible to U.S. patients, keeps a Neutral rating on Grail shares.